Recent Development in Indole Derivatives as Anticancer Agent: A Mechanistic Approach
Neha Devi1, Kamalpreet Kaur1, Avadh Biharee1
1Laboratory of Natural Products, Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda (Pb), 151001, India.
Anti-Cancer Agents in Medicinal Chemistry
|January 5, 2021
Summary
Indole derivatives show significant anti-cancer potential by targeting multiple pathways like cell cycle arrest and apoptosis. Further research into these compounds could lead to improved cancer treatments with fewer side effects.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Oncology
Background:
- Cancer remains a leading cause of mortality worldwide.
- Current cancer therapies face challenges due to severe side effects and drug resistance.
- Novel therapeutic agents with improved safety profiles are crucial for effective cancer treatment.
Purpose of the Study:
- To explore the anti-cancer mechanisms of indole derivatives.
- To identify the major molecular targets of indole derivatives in cancer therapy.
Main Methods:
- Comprehensive literature review of recent advances in indole derivative research.
- Detailed analysis of the mechanisms of action of various indole derivatives.
Main Results:
- Indole derivatives exhibit anti-cancer properties through diverse mechanisms, including apoptosis induction, aromatase inhibition, and tubulin polymerization inhibition.
- These compounds target key pathways such as estrogen receptor regulation, tyrosine kinase, topoisomerase, and the NF-kB/PI3K/Akt/mTOR pathway.
- Significant anti-cancer activity was observed against various cancer cell lines.
Conclusions:
- Indole derivatives represent a promising class of anti-cancer agents with multifaceted mechanisms of action.
- Further investigation into indole derivatives could unlock their full therapeutic potential for cancer treatment.
More Related Videos
Related Concept Videos
Inhibition of Cdk Activity
5.3K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.3K
Combination Therapies and Personalized Medicine
5.6K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
637
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
637
Mutagenicity and Carcinogenicity
1.7K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.7K
Targeted Cancer Therapies
8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.1K
Drugs that Destabilize Microtubules
2.2K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.2K


